HU194217B - Process for producing pharmaceutical compositions containing basic piroxicam salts and pharmaceutically acceptable solide vehicle - Google Patents
Process for producing pharmaceutical compositions containing basic piroxicam salts and pharmaceutically acceptable solide vehicle Download PDFInfo
- Publication number
- HU194217B HU194217B HU841574A HU157484A HU194217B HU 194217 B HU194217 B HU 194217B HU 841574 A HU841574 A HU 841574A HU 157484 A HU157484 A HU 157484A HU 194217 B HU194217 B HU 194217B
- Authority
- HU
- Hungary
- Prior art keywords
- piroxicam
- solvent
- carrier
- salt
- sodium
- Prior art date
Links
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical class OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 229960002702 piroxicam Drugs 0.000 claims abstract description 38
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims abstract description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 3
- 239000011734 sodium Substances 0.000 claims abstract description 3
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 3
- 239000002904 solvent Substances 0.000 claims description 26
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 18
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 18
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 18
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 239000001509 sodium citrate Substances 0.000 claims description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000001488 sodium phosphate Substances 0.000 claims description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 5
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims description 5
- 235000019801 trisodium phosphate Nutrition 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 abstract description 9
- 239000002552 dosage form Substances 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- RONZDIGQJSCELR-UHFFFAOYSA-M sodium;2-methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1$l^{6},2-benzothiazin-4-olate Chemical compound [Na+].[O-]C=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 RONZDIGQJSCELR-UHFFFAOYSA-M 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- FVTSYHPRVGNAQI-UHFFFAOYSA-N 2-aminoethanol;4-hydroxy-2-methyl-1,1-dioxo-n-pyridin-2-yl-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound NCCO.OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 FVTSYHPRVGNAQI-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- -1 C 1 -C 4 alkanol Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000008104 plant cellulose Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- ASTWEMOBIXQPPV-UHFFFAOYSA-K trisodium;phosphate;dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[O-]P([O-])([O-])=O ASTWEMOBIXQPPV-UHFFFAOYSA-K 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
- C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
- Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
- Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48830383A | 1983-04-25 | 1983-04-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUT34023A HUT34023A (en) | 1985-01-28 |
| HU194217B true HU194217B (en) | 1988-01-28 |
Family
ID=23939186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU841574A HU194217B (en) | 1983-04-25 | 1984-04-24 | Process for producing pharmaceutical compositions containing basic piroxicam salts and pharmaceutically acceptable solide vehicle |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP0123520B1 (OSRAM) |
| JP (1) | JPS59205375A (OSRAM) |
| KR (1) | KR840008345A (OSRAM) |
| AT (1) | ATE36531T1 (OSRAM) |
| AU (1) | AU548451B2 (OSRAM) |
| BG (1) | BG40810A3 (OSRAM) |
| CA (1) | CA1213220A (OSRAM) |
| CS (1) | CS246078B2 (OSRAM) |
| DD (1) | DD219672A5 (OSRAM) |
| DE (1) | DE3473454D1 (OSRAM) |
| DK (1) | DK165168C (OSRAM) |
| EG (1) | EG17887A (OSRAM) |
| ES (1) | ES531866A0 (OSRAM) |
| FI (1) | FI82377C (OSRAM) |
| GR (1) | GR81938B (OSRAM) |
| GT (1) | GT198404085A (OSRAM) |
| HU (1) | HU194217B (OSRAM) |
| IE (1) | IE57327B1 (OSRAM) |
| IL (1) | IL71598A (OSRAM) |
| MX (1) | MX159889A (OSRAM) |
| NO (1) | NO165177C (OSRAM) |
| NZ (1) | NZ207930A (OSRAM) |
| PH (1) | PH18864A (OSRAM) |
| PL (1) | PL144064B1 (OSRAM) |
| PT (1) | PT78473B (OSRAM) |
| RO (1) | RO88420A (OSRAM) |
| YU (1) | YU44232B (OSRAM) |
| ZA (1) | ZA843013B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582831A (en) * | 1984-11-16 | 1986-04-15 | Pfizer Inc. | Anti-inflammatory polymorphic monoethanolamine salt of N-(2-pyridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound, composition, and method of use therefor |
| HU200926B (en) * | 1988-10-28 | 1990-09-28 | Egyt Gyogyszervegyeszeti Gyar | Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules |
| GB9212450D0 (en) * | 1992-06-11 | 1992-07-22 | Indena Spa | New derivatives of non-steroidal anti-inflammatory,analgesic and/or antipyretic substances,their use and pharmaceutical formulations containing them |
| KR100446829B1 (ko) * | 2002-02-20 | 2004-09-04 | 한국유나이티드제약 주식회사 | 가용화된 피록시캄을 함유한 확산형 정제의 조성물 및그의 제조방법 |
| KR100791160B1 (ko) * | 2006-05-30 | 2008-01-02 | 조선대학교산학협력단 | 멜록시캄의 에탄올아민염 및 이를 함유하는 약제학적조성물 |
| JP2010083826A (ja) * | 2008-10-01 | 2010-04-15 | Nihon Generic Co Ltd | オキシカム系化合物を含む固形製剤を製造する方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4434164A (en) * | 1981-06-01 | 1984-02-28 | Pfizer Inc. | Crystalline benzothiazine dioxide salts |
| IN160683B (OSRAM) * | 1981-06-01 | 1987-07-25 | Pfizer |
-
1984
- 1984-04-17 RO RO84114290A patent/RO88420A/ro unknown
- 1984-04-19 AU AU27160/84A patent/AU548451B2/en not_active Ceased
- 1984-04-19 NZ NZ207930A patent/NZ207930A/en unknown
- 1984-04-19 EP EP84302666A patent/EP0123520B1/en not_active Expired
- 1984-04-19 IE IE982/84A patent/IE57327B1/en not_active IP Right Cessation
- 1984-04-19 AT AT84302666T patent/ATE36531T1/de not_active IP Right Cessation
- 1984-04-19 DE DE8484302666T patent/DE3473454D1/de not_active Expired
- 1984-04-20 IL IL71598A patent/IL71598A/xx unknown
- 1984-04-21 EG EG255/84A patent/EG17887A/xx active
- 1984-04-23 PT PT78473A patent/PT78473B/pt unknown
- 1984-04-23 PH PH30592A patent/PH18864A/en unknown
- 1984-04-24 KR KR1019840002184A patent/KR840008345A/ko not_active Ceased
- 1984-04-24 ZA ZA843013A patent/ZA843013B/xx unknown
- 1984-04-24 GT GT198404085A patent/GT198404085A/es unknown
- 1984-04-24 DD DD84262259A patent/DD219672A5/de not_active IP Right Cessation
- 1984-04-24 BG BG065219A patent/BG40810A3/xx unknown
- 1984-04-24 MX MX5834A patent/MX159889A/es unknown
- 1984-04-24 YU YU724/84A patent/YU44232B/xx unknown
- 1984-04-24 CS CS843036A patent/CS246078B2/cs unknown
- 1984-04-24 FI FI841604A patent/FI82377C/fi not_active IP Right Cessation
- 1984-04-24 NO NO841611A patent/NO165177C/no unknown
- 1984-04-24 PL PL1984247378A patent/PL144064B1/pl unknown
- 1984-04-24 DK DK204484A patent/DK165168C/da not_active IP Right Cessation
- 1984-04-24 HU HU841574A patent/HU194217B/hu not_active IP Right Cessation
- 1984-04-24 ES ES531866A patent/ES531866A0/es active Granted
- 1984-04-24 CA CA000452660A patent/CA1213220A/en not_active Expired
- 1984-04-24 GR GR74483A patent/GR81938B/el unknown
- 1984-04-25 JP JP59083624A patent/JPS59205375A/ja active Granted
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0744941B1 (en) | Process for preparing fine particle pharmaceutical formulations | |
| US5215755A (en) | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets | |
| JP4159607B2 (ja) | 大量の薬物を含有する速崩壊性及び速溶解性組成物製造のための顆粒 | |
| US5211958A (en) | Pharmaceutical composition and process for its preparation | |
| DE69620866T2 (de) | Vehrfahren zur herstellung von beta-lactam antibiotikum enthaltenden oralen dosisformen | |
| JP2002524413A (ja) | ナノ粒状ナプロキセンの新規の固体投与形態 | |
| US5320855A (en) | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets | |
| EP0345787A2 (en) | Drug in combination with flavor masking agent and method for making same | |
| US5460829A (en) | Pharmaceutical compositions based on ebastine or analogues thereof | |
| EP0306699A1 (de) | Dihydropyridin-Retard-Zubereitung | |
| EP0654484A2 (de) | Arzneimittelzubereitungen enthaltend Thioctsäure oder Dihydroliponsäure in Form von Einschlussverbindungen mit Cyclodextrinen und in Form von Granulaten, Kau- oder Brausetabletten | |
| JPH10511103A (ja) | エナラプリル塩の安定固形製剤及びその製造のための方法 | |
| RU2140272C1 (ru) | Способ получения таблеток натриевой соли фузидовой кислоты без энтеросолюбильного покрытия (варианты), таблетки и гранулят для получения таблеток натриевой соли фузидовой кислоты без энтеросолюбильного покрытия | |
| EP0123520B1 (en) | Process for preparing base salts of piroxicam deposited on a pharmaceutically-acceptable carrier | |
| JP2000516601A (ja) | 水溶性化合物及びセルロースを含有する粒状物 | |
| CN100355425C (zh) | 含有s－腺苷甲硫氨酸的稳定颗粒及其制备方法 | |
| JPH08169847A (ja) | 固形製剤 | |
| JPS5942318A (ja) | 製薬組成物、その製造法及び応用 | |
| JPH06305960A (ja) | チオウレア誘導体含有固形製剤 | |
| JPS6056974A (ja) | 環式ジチオジアセトアミドおよびその製造方法並びに薬剤 | |
| JPS62246512A (ja) | 反復作用製剤 | |
| KR20000022424A (ko) | 높은 양의 약을 함유하는, 신속-붕해되고 신속-용해되는 조성물제조용 과립 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HU90 | Patent valid on 900628 | ||
| HMM4 | Cancellation of final prot. due to non-payment of fee |